The urinary excretion of epidermal growth factor in the rat is reduced by aprotinin, a proteinase inhibitor
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The urinary excretion of epidermal growth factor in the rat is reduced by aprotinin, a proteinase inhibitor. / Jørgensen, P E; Raaberg, Lasse; Poulsen, Steen Seier; Nexø, Ebba.
I: Regulatory Peptides, Bind 31, Nr. 2, 15.11.1990, s. 115-24.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The urinary excretion of epidermal growth factor in the rat is reduced by aprotinin, a proteinase inhibitor
AU - Jørgensen, P E
AU - Raaberg, Lasse
AU - Poulsen, Steen Seier
AU - Nexø, Ebba
PY - 1990/11/15
Y1 - 1990/11/15
N2 - The present study on the rat shows that i.v. administration of the proteinase inhibitor aprotinin reduces the urinary output of immunoreactive epidermal growth factor (EGF) while the amount of immunoreactive EGF in the kidneys is increased. This indicates that the EGF-precursor in the rat kidney in vivo is processed by an aprotinin inhibitable proteinase. EGF is produced in the kidneys as a precursor with a molecular weight of approximately 130 kDa. In rat urine, nanomolar amounts of 6 kDa EGF are excreted per 24 h together with small amounts of high molecular weight forms of EGF. During i.v. administration of aprotinin the median urinary output of immunoreactive EGF is reduced to 15% of the excretion of control rats (23 pmol/2 h versus 157 pmol/2 h, P less than 0.001). Especially the excretion of 6 kDa EGF is reduced (median excretion 12 pmol/2 h versus 134 pmol/2 h, P less than 0.001). The amount of immunoreactive EGF in the kidney tissue is increased after aprotinin administration (median amount 0.11 pmol EGF/mg protein versus less than 0.04 pmol EGF/mg protein, P less than 0.001). Neither the creatinine clearance, the total urinary protein output, nor the volume of urine produced was affected by aprotinin.
AB - The present study on the rat shows that i.v. administration of the proteinase inhibitor aprotinin reduces the urinary output of immunoreactive epidermal growth factor (EGF) while the amount of immunoreactive EGF in the kidneys is increased. This indicates that the EGF-precursor in the rat kidney in vivo is processed by an aprotinin inhibitable proteinase. EGF is produced in the kidneys as a precursor with a molecular weight of approximately 130 kDa. In rat urine, nanomolar amounts of 6 kDa EGF are excreted per 24 h together with small amounts of high molecular weight forms of EGF. During i.v. administration of aprotinin the median urinary output of immunoreactive EGF is reduced to 15% of the excretion of control rats (23 pmol/2 h versus 157 pmol/2 h, P less than 0.001). Especially the excretion of 6 kDa EGF is reduced (median excretion 12 pmol/2 h versus 134 pmol/2 h, P less than 0.001). The amount of immunoreactive EGF in the kidney tissue is increased after aprotinin administration (median amount 0.11 pmol EGF/mg protein versus less than 0.04 pmol EGF/mg protein, P less than 0.001). Neither the creatinine clearance, the total urinary protein output, nor the volume of urine produced was affected by aprotinin.
KW - Animals
KW - Aprotinin
KW - Body Weight
KW - Chromatography, Gel
KW - Creatinine
KW - Diuresis
KW - Epidermal Growth Factor
KW - Female
KW - Immunohistochemistry
KW - Kidney
KW - Membrane Proteins
KW - Rats
KW - Rats, Inbred Strains
M3 - Journal article
C2 - 1702550
VL - 31
SP - 115
EP - 124
JO - Regulatory Peptides
JF - Regulatory Peptides
SN - 0167-0115
IS - 2
ER -
ID: 47488086